---
layout: post
title: "Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal"
date: 2026-02-05 18:35:32 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-02499
original_published: 2023-02-07 00:00:00 +0000
significance: 8.00
---

# Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 07, 2023 00:00 UTC
**Document Number:** 2023-02499

## Summary

The Food and Drug Administration (FDA) is announcing the renewal of the Cellular, Tissue, and Gene Therapies Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cellular, Tissue, and Gene Therapies Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 28, 2024, expiration date.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/07/2023-02499/advisory-committee-cellular-tissue-and-gene-therapies-advisory-committee-renewal)
- API: https://www.federalregister.gov/api/v1/documents/2023-02499

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
